Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription 06.02.2023 2 Am J Gastroenterol 1 Am J Med 1 Clin Infect Dis 4 Eur J Gastroenterol Hepatol 1 Gastroenterol Hepatol 3 Gut 3 Hepatology 1 J Clin Gastroenterol 3 J Hepatol 2 J Infect Dis 2 J Med Virol 2 J Virol 3 PLoS One 1 Transplant Proc 1 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. FELD JJ, Wahed AS, Fried M, Ghany MG, et al
   Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial.
   Am J Gastroenterol. 2023 Jan 13. doi: 10.14309/ajg.0000000000002176.
   PubMed         Abstract available
   
   
2. HIRODE ASG, Hansen BE, Chen CH, Su TH, et al
   Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study).
   Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002203.
   PubMed         Abstract available
   
   

   
   Am J Med

3. HALEGOUA-DEMARZIO D, Navarro V, Ahmad J, Avula B, et al
   Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN].
   Am J Med. 2023;136:200-206.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

4. HERNANDEZ-TAMAYO C, Qato DM, Jewell MP, Gounder P, et al
   COVID-19 Pandemic Associated Declines and Subsequent Increases in Hepatitis C Virus Treatment Prescriptions in Los Angeles County.
   Clin Infect Dis. 2023 Jan 31:ciad050. doi: 10.1093.
   PubMed        
   
   

   
   Eur J Gastroenterol Hepatol

5. LEE J, Chang JI, Jin YJ, Lee JH, et al
   Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002504.
   PubMed         Abstract available
   
   
6. LEE DU, Ponder R, Lee KJ, Yoo A, et al
   The nationwide trends in hospital admissions, deaths, and costs related to hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002498.
   PubMed         Abstract available
   
   
7. EBIK B, Cangul MS, Yalcin K
   What does quantitative HBsAg level mean in chronic hepatitis D infection?
   Eur J Gastroenterol Hepatol. 2023;35:320-326.
   PubMed         Abstract available
   
   
8. ZHANG P, Liu Z, Fan H, Shi T, et al
   Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease.
   Eur J Gastroenterol Hepatol. 2023;35:294-301.
   PubMed         Abstract available
   
   

   
   Gastroenterol Hepatol

9. FRAILE-LOPEZ M, Alvarez-Navascues C, Gonzalez-Dieguez ML, Cadahia V, et al
   Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
   Gastroenterol Hepatol. 2023 Jan 27:S0210-5705(23)00013.
   PubMed         Abstract available
   
   

   
   Gut

10. ROSSI M, Vecchi A, Tiezzi C, Barili V, et al
    Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.
    Gut. 2023 Jan 30:gutjnl-2022-327202. doi: 10.1136/gutjnl-2022-327202.
    PubMed         Abstract available
    
    
11. ALLWEISS L, Testoni B, Yu M, Lucifora J, et al
    Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure.
    Gut. 2023 Jan 27:gutjnl-2022-328380. doi: 10.1136/gutjnl-2022-328380.
    PubMed         Abstract available
    
    
12. TESTONI B, Ploss A
    Cracking the host functional network involved in hepatitis B virus cccDNA biology.
    Gut. 2023 Jan 27:gutjnl-2022-329185. doi: 10.1136/gutjnl-2022-329185.
    PubMed        
    
    

    
    Hepatology

13. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    PubMed        
    
    
14. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    PubMed         Abstract available
    
    
15. LISKER-MELMAN M, Wahed AS, Ghany MG, Chung RT, et al
    HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
    Hepatology. 2023;77:594-605.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

16. STRZEPKA J, Schwartz BA, Ritz EM, Aloman C, et al
    Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes.
    J Clin Gastroenterol. 2022 Dec 20. doi: 10.1097/MCG.0000000000001817.
    PubMed         Abstract available
    
    

    
    J Hepatol

17. ZOULIM F, Testoni B
    Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
    J Hepatol. 2023 Jan 27:S0168-8278(23)00029-6. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
18. MAGGIORE G, Bernard O, Mosca A, Ballot E, et al
    Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00025-9. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available
    
    
19. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    

    
    J Infect Dis

20. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
    Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
    J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
    PubMed         Abstract available
    
    
21. THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
    Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
    J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
    PubMed        
    
    

    
    J Med Virol

22. SHUI LP, Zhu Y, Duan XQ, Chen YT, et al
    HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28549.
    PubMed         Abstract available
    
    
23. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed         Abstract available
    
    

    
    J Virol

24. SASAKI-TANAKA R, Masuzaki R, Okamoto H, Shibata T, et al
    Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication.
    J Virol. 2023 Feb 2:e0198722. doi: 10.1128/jvi.01987.
    PubMed         Abstract available
    
    
25. GLASSMAN KF, Brugge JS, Purchio AF, Kakach LT, et al
    Biographical Feature: Marc S. Collett (23 May 1951-11 June 2022): the Battle against Viral Disease Has Lost a Valiant Warrior, and the World Has Lost a Splendid Human Being.
    J Virol. 2023;97:e0164322.
    PubMed        
    
    

    
    PLoS One

26. LANGAT B, Muge EK, Night D, Okoth F, et al
    Sero-prevalence of hepatitis B virus and compliance with hepatitis B vaccination schedules among outpatient clinic attendees in Nairobi.
    PLoS One. 2023;18:e0281256.
    PubMed         Abstract available
    
    
27. AGHEMO A, Persico M, D'Ambrosio R, Andreoni M, et al
    Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
    PLoS One. 2023;18:e0280165.
    PubMed         Abstract available
    
    
28. ESSAYAGH F, Essayagh T, Essayagh M, Khouchoua M, et al
    Disease burden among migrants in Morocco in 2021: A cross‑sectional study.
    PLoS One. 2023;18:e0281129.
    PubMed         Abstract available
    
    

    
    Transplant Proc

29. BURGOS MM, Grande RG, Ortega SL, Leiva IS, et al
    Impact of HCV Treatment on Recurrence of Hepatocarcinoma After Liver Transplantation.
    Transplant Proc. 2023 Jan 25:S0041-1345(22)00884.
    PubMed         Abstract available
    
    

    
    Vaccine

30. MOETLHOA B, Tjale M, Pretorius A, Hayeshi R, et al
    Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13.
    Vaccine. 2022 Dec 31:S0264-410X(22)01591-2. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: